Caffeinated Alcoholic Beverages – A Growing Public Health Problem
Study in American Journal of Preventive Medicine Explains Consequences
San Diego, CA, 30 November, 2010 – In the wake of multiple state bans on caffeinated alcoholic beverages (CABs) and an FDA warning to four companies to remove their products from the marketplace, an article published online today in the American Journal of Preventive Medicine delineates the scope of the public health problem and suggests areas of research that might help address it.
“Although several manufacturers of caffeinated beer have withdrawn their products from the market, there is no sign that young people have decreased the practice of combining alcohol and energy drinks,” commented lead author Jonathan Howland, PhD, Department of Community Health Sciences and Department of Emergency Medicine, Boston University. “Critically, CABs may increase alcohol-related risks in a number of different domains, but have been subject to very little systematic research.”
The article provides 44 references gathered from newspapers, magazines, and the scientific literature showing the current understanding of the effects of stimulants combined with alcohol. One study found that bar patrons who consumed CABs had a three-fold risk of leaving the bar highly intoxicated, compared to those who consumed alcohol without caffeine, and a fourfold risk of intending to drive after leaving the bar. Another compelling study concluded that students who consumed CABs had approximately double the risk of experiencing or committing sexual assault, riding with an intoxicated driver, having an alcohol-related accident, or requiring medical treatment.
The root of the problem may have started with so-called energy drinks. Depending on the brand, these beverages contain several stimulants, primarily caffeine, but also guarana, taurine, and sugar derivatives. Of the 577 caffeinated beverages listed on the Energy Fiend website in 2008, at least 130 contained more than the 0.02% caffeine limit for soft drinks imposed by the U.S. Food and Drug Administration (FDA).
Combining these energy drinks with alcohol became popular when marketers promoted the perception that energy drinks counteract the sedating effects of alcohol and related impairment and suggested that caffeine will increase enjoyment by allowing one to party for a longer time. According to a 2006 survey, 24% of college students reported mixing energy drinks with alcohol in the past month.
The FDA issued warning letters on November 17, 2010 to the following companies, indicating that further actions, including seizure of their products, is possible under federal law.
States with previously announced bans are New York, Washington, Iowa, Kansas, Massachusetts, Oregon, and Michigan. The FDA announcement will likely pre-empt further state bans.
The article is “Caffeinated Alcoholic Beverages: An Emerging Public Health Problem” by Jonathan Howland, PhD, Damaris J. Rohsenow, PhD, Tamara Vehige Calise, DrPH, James MacKillop, PhD, and Jane Metrik, PhD. It has been published online in advance of publication in the American Journal of Preventive Medicine, Volume 40, Issue 2 (February 2011) published by Elsevier. doi: 10.1016/j.amepre.2010.10.026
# # #
Notes For Editors
Full text of the article is available to journalists upon request; contact eAJPM@ucsd.edu. To schedule an interview with the authors please contact Lisa Chedekel, BUSPH Communications Office, at email@example.com or 617-571-6370.
About The American Journal Of Preventive Medicine
The American Journal of Preventive Medicine (www.ajpm-online.net) is the official journal of The American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials.
The American Journal of Preventive Medicine, with an Impact Factor of 4.235, is ranked 11th out of 122 Public, Environmental & Occupational Health titles and 16th out of 132 General and Internal Medicine titles according to the 2010 Journal Citation Reports© published by Thomson Reuters.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
AJPM Editorial Office
Tel: +1 858-534-9340